Similarly, a phase II study of gemcitabine combined with the HDAC inhibitor tacedinaline (CI-994) in advanced pancreatic ductal adenocarcinoma (PDAC) showed no significant improvement in OS, RR, or PFS compared to gemcitabine alone (NCT00004861) [23]. The gene discussed is HDAC9; the disease is pancreatic ductal adenocarcinoma.